News

Garuda Therapeutics Names Avanish Vellanki as New CEO

Garuda Therapeutics Names Avanish Vellanki as New CEO

Garuda Therapeutics Welcomes Avanish Vellanki as CEO

Cambridge, Massachusetts — Garuda Therapeutics, a pioneering company in blood stem cell therapies, proudly announces the appointment of Avanish Vellanki, M.B.A., as its new President and Chief Executive Officer (CEO), starting immediately. This significant decision comes as Garuda seeks to advance its innovative off-the-shelf stem cell solutions.

A New Chapter for Leadership

Avanish Vellanki succeeds the interim CEO, Dr. Adam Craig, M.D., Ph.D., MBA, who now takes on an independent role within the Board of Directors. The transition to Vellanki's leadership represents a strategic move to enhance the company’s direction and technology.

Insights from the Chairman

Eric Aguiar, M.D., Chairman of the Board, expressed his confidence in Mr. Vellanki’s ability to lead Garuda. "Avanish has a proven track record in building companies with a focus on patient welfare. His leadership will be pivotal as we continue to drive forward our hematopoietic stem cell therapy technology,” he remarked. He also thanked Dr. Craig for his steady guidance during a crucial time for the company.

Vision for the Future

Commenting on his new role, Mr. Vellanki stated, "The quality of our technology platform is unparalleled, and it holds the promise of making stem cell donors unnecessary. This innovative approach to resetting bone marrow function opens up extraordinary possibilities for patients." He highlighted his excitement to join Garuda, especially as it approaches crucial phases of clinical validation for its platform.

Continuing the Journey

Dr. Adam Craig shared his sentiments about stepping down as interim CEO, saying, "It has been a privilege to serve in this capacity. I’m confident that Avanish’s leadership will steer Garuda towards significant developments and innovations." His acknowledgment reflects a stable transition into the company’s future.

Avanish Vellanki's Background

Mr. Vellanki brings two decades of experience in healthcare and investment banking to his role at Garuda. Before joining, he was the cofounder, Chairman, and CEO of Rain Oncology, where he made substantial contributions to advancements in cancer treatments. His career kickstarted on Wall Street at Bear, Stearns & Co., where he focused on small and mid-cap biotechnology companies.

Expertise Across the Industry

Following Bear, Stearns, he transitioned into Global Healthcare Investment Banking at Citigroup, dealing with large-scale biopharmaceutical transactions. Vellanki’s hands-on industry experience includes serving at Proteolix, where he played a role in developing carfilzomib for multiple myeloma patients. His graduate studies included a B.A. from Carleton College and M.B.A. from the Carlson School of Management at the University of Minnesota.

About Garuda Therapeutics

Garuda Therapeutics is on a mission to eliminate the need for stem cell donors in blood stem cell transplants. The company's groundbreaking off-the-shelf hematopoietic stem cell therapies are designed to be HLA compatible, self-renewing, and readily available for patient use. This approach aims to address various blood disorders, offering effective treatment options that could enhance bone marrow function and improve patient outcomes.

Contact Information

For any additional details or inquiries, please reach out to Garuda Therapeutics:

Email: ir@garudatx.com

Frequently Asked Questions

Who is Avanish Vellanki?

Avanish Vellanki is the newly appointed President and CEO of Garuda Therapeutics, taking the reins from interim CEO Dr. Adam Craig.

What is Garuda Therapeutics focused on?

Garuda Therapeutics specializes in off-the-shelf blood stem cell therapies to eliminate the need for stem cell donors.

What background does Avanish Vellanki have?

He has over 20 years of experience in healthcare and investment banking, having worked at Rain Oncology and Citigroup among others.

What technologies is Garuda pursuing?

Garuda's focus is on developing hematopoietic stem cell therapies that are self-renewing and HLA compatible.

How can one contact Garuda Therapeutics?

You can reach them via email at ir@garudatx.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Quantum Space Joins $185M NASA Lunar Transport Deal

Updated Category News Views 347

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Continue Reading
NatGold Pulling NATG From MEXC Amid Security Concerns

Updated Category News Views 427

NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...

Continue Reading
Evaluating GLP-1 Telehealth? Key Questions to Consider

Updated Category News Views 451

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Continue Reading
2027 Toy of the Year Finalists Energize Play Market

Updated Category News Views 272

A Kaleidoscope of Innovation in Toys There's a familiar buzz in the air, folks. The 2027 Toy of the Year Awards finalists have been unveiled, and they're bringing a fresh wave of creativity to children's playrooms. These aren't just toys; they're miniature innovators ready to light up the market this holiday season. The reveal happened at the Chicago Toy & Game Fair and...

Continue Reading
Paris Baguette Pioneers Drive-Thru in Oklahoma

Updated Category News Views 468

Tapping The Unseen Potential In Bakery Cafes Every so often a business move comes along that makes you sit up and say, "Why the hell haven't they done this before?" Paris Baguette has finally cracked that code, rolling out its first-ever drive-thru in Moore, Oklahoma. Now, imagine yourself zipping through for a croissant without leaving the comfort of your car seat. Makes...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 89

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Adding Fireplaces: Home Comfort or Construction Headache?

Updated Category News Views 276

Sizing Up the Installation Options Slapping a fireplace into a home sounds more like a pipe dream than a practical project for most folks. But according to fireplace whiz Jimmy Smith down in North Charleston, the times are a-changin'. These days, with advances in technology, homeowners can actually pull it off without collapsing their living room walls. Nitty-Gritty:...

Continue Reading
FuelCell Faces Class Action Crunch as Deadline Looms

Updated Category News Views 192

FuelCell's Legal Storm: What to Know Now You ever get that feeling when your gut knows it all before you even finish reading the headline? Well, buckle up, because FuelCell Energy, Inc. (NASDAQ:FCEL) is staring down a potential class-action train wreck, and they ain't got much track left to skid on before the deadline hits hard on November 10th, 2026. The Crunchy Details...

Continue Reading
J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Updated Category News Views 174

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

Continue Reading
Boston STEM Expo Sparks Young Minds in Engineering

Updated Category News Views 184

If you really want to light up a kid's imagination, throw them into a room full of science experiments and let 'em have at it. That's exactly what happened at the recent Society of Women Engineers' Innovation Expo in Boston's Seaport District. The place was buzzing, and not just because of all the engineering gadgets on display—it was the energy of young minds...

Continue Reading

Top 5 Most Recently Viewed Articles

Bio-Thera and Tabuk Join Forces for BAT2206 Biosimilar Launch

Updated Category News Views 136

Bio-Thera Solutions Partners with Tabuk Pharmaceuticals Bio-Thera Solutions Inc. (688177:SH) has announced a significant partnership with Tabuk Pharmaceutical Manufacturing Company, a respected player in the pharmaceutical industry. This collaboration marks a new chapter in the commercialization of BAT2206, a proposed biosimilar to Jansen's Stelara. Understanding BAT2206...

Continue Reading
Unlocking Innovative Trading Solutions with XploraDEX's $XPL

Updated Category News Views 381

XploraDEX: Transforming Trading on the XRP Ledger XploraDEX is on a mission to revolutionize the trading landscape on the XRP Ledger by implementing an intelligent, adaptive decentralized finance (DeFi) infrastructure. With the XRP ecosystem recognized for its remarkable speed and efficiency, many traders have long sought advanced solutions to fully harness its potential....

Continue Reading
Ferrari N.V. Updates on Share Buyback Program Progress

Updated Category News Views 89

Share Buyback Program at a Glance Ferrari N.V. (NYSE/EXM: RACE) has provided an update on its ongoing share buyback program. Launched in 2022 with a total budget of approximately Euro 2 billion, the program is unfolding in tranches designed to support a disciplined capital structure and steady shareholder returns. The continued rollout underscores Ferrari’s intent to...

Continue Reading
Global Ship Lease Announces Generous Dividend for Investors

Updated Category News Views 148

Global Ship Lease Declares Significant Dividend In a noteworthy announcement, Global Ship Lease, Inc. (NYSE:GSL) recently disclosed that its Board of Directors has approved a cash dividend of $0.546875 for each depositary share. Each depositary share represents a 1/100th interest in a share of the Company’s 8.75% Series B Cumulative Redeemable Perpetual Preferred...

Continue Reading
iBio Inc. Showcases Innovative Antibody Developments Soon

Updated Category News Views 194

Exciting Presentations from iBio Inc. iBio, Inc. (NASDAQ: IBIO), a pioneering biotechnology company, is gearing up to present breakthrough research on its Activin E antibody. This development showcases its commitment to addressing critical health challenges like obesity. Recently, Cory Schwartz, Ph.D., the Director of Research and Early Development at iBio, announced his...

Continue Reading